News Release Archive

By Date

April 04, 2012 New Data Analyses for VICTRELIS (boceprevir) Will Be Presented at The International Liver Congress / 2012 EASL Annual Meeting
April 03, 2012 Randy Jackson Partners with Merck to Urge People with Type 2 Diabetes to Take Their Diabetes to Heart
April 02, 2012 Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
March 28, 2012 Merck Appoints Michael J. Holston as Chief Ethics and Compliance Officer
March 28, 2012 Merck Provides Update on IMPROVE-IT Trial
March 27, 2012 Merck to Hold First-Quarter 2012 Sales and Earnings Conference Call on Aprill 27
March 24, 2012 In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
March 20, 2012 Merck and Safe Water Network Launch Initiative to Improve Water Access and Help Reduce the Impact of Water-Borne Disease in India
March 15, 2012 Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)
March 13, 2012 Merck to Present at the Barclays Capital 2012 Global Healthcare Conference
March 6, 2012 Results from Investigational Studies with VICTRELIS (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1
March 6, 2012 Merck Confirms 2012 Full-Year Guidance
March 5, 2012 Merck's Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
March 5, 2012 Merck to Present at the Cowen & Company 32nd Annual Health Care Conference
March 5, 2012 Merck Receives 2012 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
Feb. 28, 2012 Merck Announces Second-Quarter 2012 Dividend
Feb. 28, 2012 Merck Provides Information on FDA Post-Marcheting Requirement for Sitagliptin
Feb. 28, 2012 Merck to Present at the 2012 Citi Global Healthcare Conference
Feb. 27, 2012 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey
Feb. 16, 2012 Singer Jon Secada Joins Merck and American Liver Foundation's 'Tune In to Hep C' Public Awareness Campaign
Feb. 15, 2012 Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil
Feb. 14, 2012 Merck to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb. 13, 2012 FDA Approves ZIOPTAN (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication
Feb. 10, 2012 Kentucky Court Of Appeals Reverses Certification of a Class of Plaintiffs Seeking Reimbursement for Vioxx® Costs
Feb. 8, 2012 Merck Informs Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS with Ritonavir-Boosted HIV Protease Inhibitors
Feb. 8, 2012 Thomas E. Shenk To Retire From Merck's Board of Directors
Feb. 7, 2012 Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
Feb. 7, 2012 The NAMES Project Foundation and Merck Launch "Call My Name" National Tour AIDS Panel Making Workshop to Focus Attention on HIV/AIDS Crisis in African American Communities
Feb. 6, 2012 Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
Feb. 2, 2012 FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
Feb. 2, 2012 Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
Jan. 26, 2012 Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2
Jan. 25, 2012 New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Jan. 19, 2012 Merck Resolves Vioxx® Litigation in Canada
Jan. 9, 2012 Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan. 6, 2012 TFDA Approves Merck’s ISENTRESS® (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy
Jan. 04, 2012 Merck to Present at Goldman Sachs 2012 Healthcare Event
Dec. 21, 2011 Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV
Dec. 15, 2011 Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection
Dec. 12, 2011 Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting
Dec. 6, 2011 Merck Establishes New MSD R&D Asia Headquarters
Dec. 5, 2011 Merck for Mothers and PATH Collaborate to Identify Innovations that Save Mothers' Lives
Nov. 22, 2011 Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney's Office for the District of Massachusetts Related to Vioxx®
Nov. 13, 2011 Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM
Nov. 11, 2011 Merck and Partners Make Progress In Long-Term Commitment to End River Blindness
Nov. 10, 2011 Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing
Nov. 10, 2011 Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth
Nov. 10, 2011 Merck to Present at the 2011 Credit Suisse Healthcare Conference
Nov. 9, 2011 Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States - A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
Nov. 5, 2011 Interim Data for Merck's VICTRELIS (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
Nov. 2, 2011 FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease
Oct. 31, 2011 Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report
Oct. 28, 2011 Merck Announces Third Quarter 2011 Financial Results
Oct. 26, 2011 New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
Oct. 25, 2011 CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
Oct. 24, 2011 Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fuMarchte dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
Oct. 20, 2011 Interim Phase IIb Data for Merck's VICTRELIS (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting
Oct. 13, 2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
Oct. 7, 2011 FDA Approves Merck's JUVISYNC (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease
Oct. 6, 2011 Merck Announces Retirement of Chairman and Former CEO Richard T. Clark
Oct. 5, 2011 FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor
Oct. 4, 2011 Merck Adds New Medication Adherence Resources to Consumer Web Site
Oct. 3, 2011 Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium)
Sept. 30, 2011 Merck Announces New Data Analyses for VICTRELIS (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
Sept. 30, 2011 Merck Publishes 2010 Global Corporate Responsibility Report
Sept. 30, 2011 Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28
Sept. 28, 2011 Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
Sept. 27, 2011 Merck Names Cuong Viet Do as Chief Strategy Officer
Sept. 23, 2011 Study of ZOLINZA® (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet PriMarch Endpoint
Sept. 20, 2011 Merck Joins Global Fight to Help Save Women's Lives During Pregnancy and Childbirth
Sept. 19, 2011 New Data on Odanacatib, Merck's Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research
Sept. 19, 2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race
Sept. 14, 2011 Merck to Present at Bank of America Merrill Lynch Global Healthcare Conference
Sept. 13, 2011 Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations
Sept. 13, 2011 Merck and BGI Establish Strategic Collaboration Focused on BioMarchers and Genomic Technologies
Sept. 13, 2011 Merck Provides Update on the IMPROVE-IT Trial
Sept. 12, 2011 Merck to Present at Morgan Stanley Global Healthcare Conference
Sept. 7, 2011 Merck Statement on FOSAMAX® (alendronate sodium) Product Liability Trial
Aug. 26, 2011 Texas Supreme Court Finds for Merck in VIOXX® Case
Aug. 23, 2011 Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health
Aug. 18, 2011 Merck and ARIAD Announce European Medicines Agency Accepts Marcheting Authorization Application for Ridaforolimus, Investigational mTOR Inhibitor
Aug. 3, 2011 Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)
July 29, 2011 Merck Announces Second Quarter 2011 Financial Results
July 28, 2011 Merck Recognizes World Hepatitis Day With Partnerships and Grants to Support Global Hepatitis C Community
July 27, 2011 Latest Merck Manual Delivers Trusted Health Care Information in Print and Electronic Formats
July 26, 2011 Merck Announces Fourth Quarter 2011 Dividend
July 26, 2011 R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and The American Liver Foundation to Turn Up the Volume Around Hep C
July 26, 2011 Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
July 21, 2011 Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture
July 20, 2011 Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C
July 18, 2011 VICTRELIS (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C
July 18, 2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1
July 11, 2011 Merck to Participate in New Research Efforts to Eradicate HIV
July 1, 2011 Merck Receives Approval to Marchet GARDASIL®, ZOLINZA® and CUBICIN® in Japan
June 30, 2011 Merck to Hold Second-Quarter 2011 Sales and Earnings Conference Call on July 29
June 29, 2011 Merck Announces New Name for its Animal Health Division
June 28, 2011 UPS and Merck Expand Their Distribution and Logistics Agreement
June 25, 2011 In a New Post-Hoc Analysis Based on the AACE/ACE Diabetes Algorithm Significantly More Patients Achieved Blood Sugar Goals with Initial Therapy with Merck's Diabetes Medicine JANUMET® (sitagliptin/metformin HCl) Compared to Metformin Alone
June 21, 2011 Legendary Musician Gregg Allman Joins Merck and American Liver Foundation to Launch Tune In to Hep C Public Awareness Campaign
June 13, 2011 Merck and Hanwha Chemical Corporation Establish Global Strategic Collaboration to Develop and Commercialize Biosimilar Candidate
June 10, 2011 Merck Statement Regarding FDA Approval of Changes to Trade Packaging Design for Several Medicines from Merck
June 8, 2011 Actress JoAnna Garcia Swisher "Goes There" in a New Campaign with Merck to Motivate Women to "Get Real" When Talking to Their Physicians about Their Health
June 8, 2011 U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose -- 80 mg -- and Updated Drug Interaction Information
June 8, 2011 U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose -- 80 mg -- and Updated Drug Interaction Information
June 8, 2011 Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
June 7, 2011 Merck to Present at Goldman Sachs 32nd Annual Healthcare Conference
June 7, 2011 Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies
June 6, 2011 Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
June 5, 2011 Merck Commends GAVI Alliance on Continued Efforts to Improve Access
June 2, 2011 Merck Signs on to United Nations CEO Water Mandate
May 31, 2011 Merck to Present at Sanford Bernstein 27th Strategic Decisions Conference
May 24, 2011 Merck Announces Third Quarter 2011 Dividend
May 20, 2011 CHMP Issues Positive Opinion for Merck's VICTRELIS (boceprevir), Oral Hepatitis C Virus (HCV) Protease Inhibitor
May 17, 2011 Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C
May 16, 2011 Merck Completes Acquisition of Inspire Pharmaceuticals, Inc.
May 13, 2011 FDA Approves Merck's VICTRELIS (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
May 13, 2011 Merck Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered
May 9, 2011 Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus
May 2, 2011 Merck’s Investigational Prostaglandin Analogue Ophthalmic Medication Tafluprost Meets PriMarch Endpoint in Phase III Study
May 2, 2011 Merck to Present at Deutsche Bank 36th Annual Healthcare Conference
April 29, 2011 Merck Announces First Quarter 2011 Financial Results
April 28, 2011 Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire
April 27, 2011 VICTRELIS (boceprevir) Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection
April 27, 2011 Merck Announces New $5 Billion Share Repurchase Program
April 25, 2011 Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing
April 21, 2011 Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases
April 15, 2011 Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
April 15, 2011 Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®
April 15, 2011 Merck Reaffirms 2011 Non-GAAP EPS Target
April 11, 2011 FDA Approves Merck's SYLATRON (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement
April 11, 2011 Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Marchets
April 11, 2011 Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
April 6, 2011 U.S. Prescribing Information for GARDASIL® Updated; Indication Not Granted for Use in Adult Women
April 5, 2011 Merck to Acquire Inspire Pharmaceuticals, Inc.
April 1, 2011 Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on Aprill 29
March 31, 2011 Jury Finds for Merck and Other Defendants on the Key Issue in an Environmental Contamination Lawsuit
March 24, 2011 Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck
March 22, 2011 Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health
March 16, 2011 Merck Receives 2011 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
March 15, 2011 Merck to Present at Barclays Capital 2011 Global Healthcare Conference
March 10, 2011 SisterLove, Inc. and Merck Launch "Everyone Has A Story" Series
March 7, 2011 Merck to Present at Cowen and Company's 31st Annual Health Care Conference
Feb. 28, 2011 Merck to Present at Citi 2011 Global Health Care Conference
Feb. 28, 2011 Fujifilm to Acquire Merck Biomanufacturing Network
Feb. 22, 2011 Merck Announces Second Quarter 2011 Dividend
Feb. 14, 2011 Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial
Feb. 03, 2011 Merck Announces Fourth Quarter and Full Year 2010 Financial Results
Jan. 25, 2011 John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age
Jan. 18, 2011 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey State Court
Jan. 12, 2011 Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates
Jan. 11, 2011 Merck to Present at the 29th Annual J.P. Morgan Healthcare Conference
Jan. 4, 2011 Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3
Dec. 7, 2010 Merck Prices $2.0 Billion Debt Offering
Dec. 2, 2010 Merck to Acquire SMarchCells, Inc.
Nov. 30, 2010 Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T. Clark to Continue as Chairman
Nov. 23, 2010 Merck Announces First-Quarter 2011 Dividend
Nov. 19, 2010 Merck Wins Another Federal FOSAMAX® (alendronate sodium) Bellwether Trial
Nov. 11, 2010 Merck and Partners Make Progress In Long-Term Commitment To End River Blindness
Oct. 29, 2010 Merck Announces Third-Quarter 2010 Financial Results
Oct. 28, 2010 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
Oct. 13, 2010 Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach
Oct. 13, 2010 Tenth Edition of The Merck Veterinary Manual Debuts
Oct. 12, 2010 Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Marchets Outside of the United States, China and Japan
Oct. 4, 2010 Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX® (alendronate sodium) Case
Oct. 1, 2010 Merck to Hold Third-Quarter 2010 Sales and Earnings Conference Call on Oct. 29
Sept. 30, 2010 Merck to Appeal Verdict in Massachusetts Medicaid Case
Sept. 29, 2010 Why So Shy? What Females of the Facebook Generation Are Not Sharing in the OB/GYN Office that Could Affect Their Health
Sept. 22, 2010 Merck Significantly Expands its Patient Assistance Program Offerings to Provide Access to More Medicines for People in Need
Sept. 16, 2010 Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign
Aug. 24, 2010 Merck Provides New Funding to Fight HIV/AIDS in Botswana
Aug. 12, 2010 Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock
Aug. 10, 2010 Merck Partners With Sesame Workshop on National Program to Encourage Healthy Eating Habits in Families with a Limited Budget
Aug. 10, 2010 Black AIDS Institute, in Partnership with Merck, Launches Dynamic National HIV/AIDS Treatment and Care Advocacy Network
July 30, 2010 Merck Announces Second-Quarter 2010 Financial Results
July 27, 2010 Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to Hepatitis C Therapy
July 27, 2010 Merck Announces Fourth-Quarter 2010 Dividend
July 27, 2010 Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture
July 27, 2010 Sinopharm and Merck Sign Statement of Mutual Intent
July 8, 2010 Merck Details Plans to Advance Integration of R&D, Manufacturing and Business Operations Worldwide
June 30, 2010 Merck to Hold Second-Quarter 2010 Sales and Earnings Conference Call on July 30
June 29, 2010 Merck Wins Case Filed by Louisiana Attorney General Involving VIOXX®
June 25, 2010 Merck Challenges Verdict in Federal FOSAMAX® (alendronate sodium) Trial
June 24, 2010 Merck to Expand Business in South Africa
June 21, 2010 UNCF/MERCK Science Initiative Awards Scholarships and Fellowships to African American in Bioscience
June 7, 2010 Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
May 26, 2010 Merck Announces Third Quarter 2010 Dividends
May 11, 2010 Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy for Growth in Emerging Marchets
May 11, 2010 Merck Highlights Robust Late-Stage Pipeline, Global Business Strategy and Progress of Integration
May 5, 2010 Merck Wins Second Federal FOSAMAX® (alendronate sodium) Bellwether Trial
May 5, 2010 Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation Partner on Vaccination Program with GARDASIL® for Girls and Young Women of Bhutan
May 4, 2010 Merck Announces First-Quarter 2010 Financial Results
April 28, 2010 Merck Announces Senior Management Appointments
April 27, 2010 U.S. Supreme Court Affirms Lower Court Decision on Merck Federal Securities Class Action
April 26, 2010 Nycomed and Merck & Co., Inc., Announce Commercialization Agreements For Daxas® in Europe and Canada
April 23, 2010 Merck Provides Information on Impact of U.S. Health Care Reform Legislation
April 21, 2010 Merck Obtains Exclusive Rights to Marchet and Distribute MassBiologics' Tetanus-Diphtheria (Td) Vaccine in the U.S.
April 19, 2010 Merck Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
April 12, 2010 Statement on Vioxx® Consumer Product Trial in U.S. District Court for the Eastern District of Louisiana.
April 7, 2010 Merck to Hold First-Quarter 2010 Sales and Earnings Conference Call on May 4

The information contained in each news release posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates.

By Category

Prescription Medicine News
April 04, 2012 New Data Analyses for VICTRELIS (boceprevir) Will Be Presented at The International Liver Congress / 2012 EASL Annual Meeting
March 6, 2012 Results from Investigational Studies with VICTRELIS (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1
Feb. 13, 2012 FDA Approves ZIOPTAN (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication
More Prescription Medicine News

Vaccine News
April 02, 2012 Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
Patient Product Information
Oct. 26, 2011 New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
Patient Product Information
Oct. 25, 2011 CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
Patient Product Information
More Vaccine News

Research and Development News
March 24, 2012 In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
March 15, 2012 Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)
March 5, 2012 Merck's Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
More Research & Development News
Derechos reservados ©2012 Merck Sharp & Dohme Corp. Una subsidiaria de Merck & Co., Inc., Kenilworth, NJ, USA. Todos los derechos reservados.

TRUSTe - Click to Verify